There is a critical need for technology that will allow the isolation of high quality RNA from histologically preserved clinical samples. The most commonly used fixative, neural buffered formalin severely compromises subsequent isolation of intact nucleic acids. The need for improvement is most acute for techniques that require intact RNA for expression analysis. We proposed a three-track approach. First, we will develop and optimize procedures for the extraction and purification of high quality, reverse- transcription competent RNA from formalin-fixed samples. Second, we will develop new fixation technologies, fully compatible with nucleic acid isolation, by screening existing cross-linking reagents for suitability as fixatives. Finally, we propose synthesizing a novel reversible cross-linking, glutaraldehyde derivative. Ambion, a leading supplier of products for RNA quantitation and analysis, intends to market nucleic acid compatible tissue fixatives and RNA isolation products to the biomedical research community. We believe they will be widely utilized in both basic research and clinical laboratories.

Proposed Commercial Applications

Improvements to current technologies will allow high quality RNA to be isolated from histologically preserved samples. Ambion will develop and market this methodology in kit form.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA083477-01
Application #
6016576
Study Section
Special Emphasis Panel (ZCA1-SRRB-C (M2))
Program Officer
Couch, Jennifer A
Project Start
1999-08-01
Project End
2001-06-30
Budget Start
1999-08-01
Budget End
2001-06-30
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ambion, Inc.
Department
Type
DUNS #
198680068
City
Austin
State
TX
Country
United States
Zip Code
78744